Search results
Why US Drug Giant Bristol Myers Squibb Stock Trading Up On Monday - Bristol-Myers Squibb (NYSE:BMY)
Benzinga· 19 hours agoMedian PFS was 5.5 months for Krazati compared to 3.8 months for docetaxel.
...I/Ib Study of Alisertib in Advanced EGFR-Mutated Lung Cancer - Puma Biotechnology (NASDAQ:PBYI)
Benzinga· 18 hours agoCDT.
...Results for Ifebemtinib in Combination with Garsorasib in Non-Small Cell Lung Cancer (NSCLC) with...
WKBN 27 Youngstown· 5 days ago3% and DCR of 96.8% Ifebemtinib is a highly selective, orally administered...2024 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnology company ...
'Outstanding' Results for Osimertinib: Stage III EGFR+ NSCLC
Medscape· 7 hours agoResults from the LAURA trial will change practice once its label gets expanded, experts said at the...
AMGEN TO PRESENT INNOVATIVE RESEARCH FROM ITS ROBUST ONCOLOGY PORTFOLIO AT ASCO 2024
Morningstar· 7 days agoData From Newly FDA-Approved IMDELLTRA™ (tarlatamab-dlle) Further Reinforce Leadership in Bispecific T-Cell Engagers Overall Survival Data from Phase < ...
Unprecedented PFS Results in ALK-Positive Lung Cancer Trial
MedPage Today· 4 days agoFive-year results from a phase III trial had experts gushing over lorlatinib's (Lorbrena)...
...Moderna & Merck Announce 3-Year Data For...in Recurrence-Free Survival & Distant Metastasis......
Digital Journal· 1 day agoAt a median planned follow-up of the Phase 2b study at 34.9 months, mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 49% and the risk of distant metastasis ...
Merck's Multi-Billion Cancer Drug Keytruda Aces Late-Stage Breast Cancer Study (UPDATED)
Benzinga· 7 days agoTuesday, Merck & Co Inc MRK released topline data from hase 3 KEYNOTE-522 trial of Keytruda in...
Moderna, Merck Reveal Three Year Data For Individualized Cancer Therapy In High-Risk Melanoma...
Benzinga via Yahoo Finance· 20 hours agoThe study is evaluating mRNA-4157 (V940), an investigational individualized neoantigen therapy...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 3 days agoThe results showed a 12-month overall survival (“OS”) rate of 69%, a median overall survival (“mOS”) of 17.5 months, and a 30% overall ...